IL7 and acute lymphoblastic leukemia: Interleukin‐7 (IL‐7), IL‐7Rα, and γc receptors form a ternary complex essential for signaling pathways involved in normal lymphoid development and leukemogenesis.[31] Therapeutics targeting the IL‐7/IL‐7R axis may, therefore, benefit patients with acute lymphoblastic leukemia or autoimmune diseases.[32] We aimed to target two distinct IL‐7Rα epitopes, that we refer to as site 1 and site 2 (Figure 4A).